header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

ARTHROPLASTY IN HIV INFECTED PATIENTS – A 5 YEAR FOLLOW UP



Abstract

The increased prevalence of HIV has increased awareness and concern for the diagnosis and treatment of patients requiring total joint arthroplasty. Collective experience with HIV and arthroplasty at any institution is small and limited. This study evaluates the clinical outcome of arthroplasty in HIV infected patients.

Between July 2000 and August 2001, we treated 14 patients (4 female) and with uncemented total hip replacement. (Mean age of 42 years). Informed consent was obtained before HIV testing and counselling was provided for all patients. Patients were classified according to the WHO and CDC classification. All patients were operated on by a single surgeon using the Hardinge approach.

14 Patients were followed up with a mean follow up 62 months. The pre-lymphycyte subset analysis was TLC-2.24, CD4 425, CD8 873, CD4/CD8-0.52. All patients were fully ambulant. One patient sustained a periprosthetic fracture following a high energy car accident which was treated non operatively. Three patients have dropped their CD4 count to below 200 and are presently receiving antiretroviral treatment. There was no loosening, infection or dislocation.

The literature on complications associated with arthroplasty in HIV infected patients is inconsistent. A few authors have reported a 40% incidence of infection with total joint replacement. In this series there were no infections, and the outcome of total joint arthroplasty depends on the nutritional status of the patient, the stage of the under lying disease, as well as previous surgery and co-morbidities. Orthopaedic Surgeons should be aware of the increasing prevalence of HIV infection, and that arthroplasty in these patients can be safely performed with minimum complications.

Correspondence should be addressed to: LĂ©ana Fourie, CEO SAOA, PO Box 12918, Brandhof 9324 South Africa.